San Francisco, 31 December 2024: The Report Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type ( Autologous Therapies, Non-Stem Cell Therapies, Non-Stem Cell Therapies), By Therapeutic Area (Oncology, Dermatology), By Region, And Segment Forecasts, 2030 - 2030

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2030 to 2030, according to a new report by Grand View Research, Inc. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Some key factors driving the market growth include numerous immunological advantages, a rise in the proportion of the geriatric population across the globe, and a reduced risk of autologous cell therapy rejection. Autologous cell therapy is widely used in a range of diseases such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others.

Request sample report of Autologous Cell Therapy Market@ https://www.grandviewresearch.com/industry-analysis/autologous-cell-therapy-market-report/request/rs1

The autologous approach significantly reduces the risk of therapy rejection, which is a major advantage over allogeneic therapies (using donor cells). This improves patient outcomes and simplifies the path to regulatory approval. The therapy minimizes the risk of immune rejection by using the patient's cells, creating a safer treatment option. This approach has shown considerable promise, particularly in cancer treatments, where immune compatibility is crucial for therapy success. Personalized treatments leveraging these advantages are becoming increasingly sought after, reflecting a broader trend toward individualized medicine.

Autologous Cell Therapy Market Report Highlights

• The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.
• The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.
• The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.
• Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Moreover, the global population of individuals aged 65 and older is projected to more than double by 2050, reaching over 1.5 billion. This demographic shift increases the prevalence of age-related diseases such as cardiovascular disorders and neurodegenerative diseases. These conditions are key application areas for autologous cell therapy, which, in turn, stimulates market growth as demand for effective treatments rises.

Autologous Cell Therapy Market Report Scope

Autologous cell therapies' clinical and regulatory efficiency encourages investment and innovation in this sector, responding to the critical need for compatible and effective therapeutic options.In November 2023, Novartis secured global rights to a selection of Legend Biotech’s CAR-T cell therapies, including a promising candidate for lung cancer and large cell neuroendocrine carcinoma, in a deal worth over USD 1.0 billion. This agreement allows Novartis to leverage its T-Charge platform to develop and manufacture these therapies.